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Course of ICD related to filaggrin and atopy
This prospective cohort study included 327 (71.2%) atopic 
individuals and 132 nonatopic individuals. Sixty-eight patients 
showed a mutation in the filaggrin gene (FLG) alleles R501X, 
R2447X, S3247X and 2282del4 (60 atopic and eight nonatop-
ic). Nonatopic patients with irritant contact dermatitis (ICD) 
responded well to therapeutic approaches, while atopy sta-
tus made subjects more resistant to therapy, resulting in lower 
rates of recovery and job continuation, and higher use of topi-
cal corticosteroids. Carriage of FLG loss-of-function mutations 
in combination with atopy worsened the course. The risk of 
abandoning one’s profession in this group was significantly 
increased when compared with ‘pure’ ICD (odds ratio 3.1) 
after 3 years. It is concluded that in the presence of atopic der-
matitis, FLG mutations seem to be a modifier of the severity of 
the clinical course in ICD. Br J Dermatol 2012; 167: 302–09.
Psoriasis, stroke and myocardial infarction
Seven cohort studies were included in the meta-analysis, five 
considered good quality and two fair. The overall combined 
relative risk for psoriasis and composite vascular endpoint was 
1.2 (95% confidence interval 1.1–1.31). Subgroup analysis 
maintained this significance with respect to stroke and myo-
cardial infarction (MI) individually. Sensitivity analysis and the 
‘trim and fill’ method yielded similar results. No evidence of 
publication bias was observed. Results suggest that psoriasis 
significantly increases the risk of stroke and MI. The increase is 
probably independent of conventional cardiovascular risk fac-
tors. Br J Dermatol 2012; 167: 1345–50.
Risk of second primary melanoma, Netherlands 
Cancer Registry, 1989–2008
This is the first large, European, population-based study that 
has observed long-term increased risks of a second primary 
invasive melanoma after a first in situ (20-year cumulative 
risk = 6.2%) and invasive melanoma (20-year cumulative 
risk = 5.0%). A total of 10,765 patients with in situ melano-
ma and 46,700 with invasive melanoma were included in 
this study. The relative risk of developing any melanoma (in 
situ or invasive) after any first melanoma (measured as stan-
dardized incidence ratio, SIR) varied from 12.4-fold to 26.4-
fold increase compared with the general population. SIRs and 
absolute excess risk remained elevated up to 20 years after the 
first melanoma. Br J Dermatol  2012; 167: 1321–30.
IL2RA and TNF/LTA associated with  
alopecia areata
Redler et al. investigated the association between alopecia 
areata (AA) and selected cytokine genes using a sample of 768 
patients with AA and 658 controls of Central European origin. 
Significant association was found for two variants within both 
IL2RA and TNF/LTA. In the overall sample, the most signifi-
cant results were obtained for the IL2RA variant rs706778 and 
the TNF/LTA locus variant rs1800629. In subgroup analyses, 
according to severity, age at onset and family history these 
effects were stronger in the severely affected patients, with 
the lowest P-values being obtained for rs706778 (P = 3.8 x 
10−6). Results support the hypothesis that the cytokine gene 
IL2RA and the TNF/LTA region influence susceptibility to AA 
and determine a severe disease course, and that AA is an auto-
immune disease. Br J Dermatol 2012; 167: 1360–65.
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